Oxford BioMedica, a gene-based biopharmaceutical company, has made a strategic decision to close the US trial of its TroVax product on patients with progressive hormone refractory prostate cancer (HRPC) because recruitment has been much slower than originally anticipated. [10 Oct '12]
Brady, a provider of trading, risk management and settlement solutions to the energy, metals and commodities sectors, has said that it is in a payment dispute over software with a customer that it signed in 2011. [31 Aug '12]
eXpansys, the online electronics retailer has delivered a 33 per cent increase in turnover in the 12 months to the end of April. Total revenues for the year were 108.5m pounds, up 24pc on a like-for-like basis. Profits before tax were 4.3m pounds, a rise of 27pc on the prior year. The market had clearly been expecting better, the stock was down 3.8pc at 10:34. [8 Aug '12]
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.